Yonsei Med J.  2015 May;56(3):712-718. 10.3349/ymj.2015.56.3.712.

Mean Platelet Volume Is Elevated in Patients with Psoriasis Vulgaris

• Kim DS
• Lee J
• Kim SH
• Kim SM
• Lee MG

• KMID: 2450345
• DOI: http://doi.org/10.3349/ymj.2015.56.3.712

Abstract

PURPOSE
This retrospective study was done to investigate the mean platelet volume (MPV) level in patients with psoriasis vulgaris and its relationship with disease severity.
MATERIALS AND METHODS
We undertook a cross-sectional study on 176 patients and 101 healthy controls to examine the association between MPV and psoriasis. Various clinical and laboratory parameters were analyzed and compared.
RESULTS
Platelet distribution width and MPV were significantly higher in patients with psoriasis than controls. In addition, there was positive correlation between Psoriasis Area Severity Index (PASI) and MPV. When psoriasis patients were grouped into mild psoriasis (PASI<10) and moderate to severe psoriasis (PASI> or =10), the MPV of the latter group was significantly elevated. Nevertheless, patients with higher MPV level (MPV> or =10.4 fL) did not show higher PASI than lower MPV level (MPV<10.4 fL). MPV levels significantly decreased after improvements of psoriasis with various treatments. The variations of MPV and PASI also showed significant correlation.
CONCLUSION
We have shown that MPV is increased in psoriasis patients and correlates with disease severity. Therefore, MPV levels may be considered as a marker of disease severity of psoriasis.

Keyword

Psoriasis; mean platelet volume; platelet distribution width

MeSH Terms

Adult
Blood Sedimentation
Cross-Sectional Studies
Female
Humans
Male
*Mean Platelet Volume
Middle Aged
Platelet Count
Psoriasis/*blood/*physiopathology
Retrospective Studies
Severity of Illness Index

Figure

• 

  Fig. 1 The correlations between PASI and (A) MPV, (B) ESR, (C) uric acid, (D) CRP in patients with psoriasis are depicted. PASI, Psoriasis Area Severity Index; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.

• 

  Fig. 2 Psoriasis patients are divided into mild group (PASI<10) and moderate, severe group (PASI≥10). Values and mean values of MPV are shown. PASI, Psoriasis Area Severity Index; MPV, mean platelet volume.

• 

  Fig. 3 Psoriasis patients are divided into two groups according to their MPV value (MPV<10.4 fL and MPV≥10.4 fL). PASI scores of the patients in each group are shown. PASI, Psoriasis Area Severity Index; MPV, mean platelet volume.

• 

  Fig. 4 (A) The MPV levels of psoriasis individuals were evaluated before and after the treatments. (B) The correlation between the variations of PASI (ΔPASI) and the variation of MPV (ΔMPV) was analyzed. PASI, Psoriasis Area Severity Index; MPV, mean platelet volume.

Reference

1. von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res. 2007; 100:27–40.

2. Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases. Platelets. 2008; 19:317–321.

3. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011; 17:47–58.

4. Pauling JD, O'Donnell VB, Mchugh NJ. The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis. Platelets. 2013; 24:503–515.

5. Balbaloglu O, Korkmaz M, Yolcu S, Karaaslan F, Beceren NG. Evaluation of mean platelet volume (MPV) levels in patients with synovitis associated with knee osteoarthritis. Platelets. 2014; 25:81–85.

6. Liang QC, Jin D, Li Y, Wang RT. Mean platelet volume and platelet distribution width in vascular dementia and Alzheimer's disease. Platelets. 2014; 25:433–438.

7. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009; 361:496–509.

8. Canpolat F, Akpinar H, Eskioğu F. Mean platelet volume in psoriasis and psoriatic arthritis. Clin Rheumatol. 2010; 29:325–328.

9. Saleh HM, Attia EA, Onsy AM, Saad AA, Abd Ellah MM. Platelet activation: a link between psoriasis per se and subclinical atherosclerosis--a case-control study. Br J Dermatol. 2013; 169:68–75.

10. Villanova F, Di Meglio P, Nestle FO. Biomarkers in psoriasis and psoriatic arthritis. Ann Rheum Dis. 2013; 72:Suppl 2. ii104–ii110.

11. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013; 169:266–282.

12. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004; 150:917–928.

13. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005; 2005:273–279.

14. Boehncke WH. Perspective: Don't be superficial. Nature. 2012; 492:S55.

15. Berrettini M, Parise P, Constantini V, Grasselli S, Nenci GG. Platelet activation in psoriasis. Thromb Haemost. 1985; 53:195–197.

16. Hayashi S, Shimizu I, Miyauchi H, Watanabe S. Increased platelet aggregation in psoriasis. Acta Derm Venereol. 1985; 65:258–262.

17. Leader A, Pereg D, Lishner M. Are platelet volume indices of clinical use? A multidisciplinary review. Ann Med. 2012; 44:805–816.

18. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006; 99:1293–1304.

19. Gear AR, Camerini D. Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation. 2003; 10:335–350.

20. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA. Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood. 1993; 81:2492–2495.

21. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, Nockowski P, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008; 394:7–21.

22. Teranishi Y, Mizutani H, Murata M, Shimizu M, Matsushima K. Increased spontaneous production of IL-8 in peripheral blood monocytes from the psoriatic patient: relation to focal infection and response to treatments. J Dermatol Sci. 1995; 10:8–15.

23. Pietrzak A, Kozioł-Montewka M, Lecewicz-Toruń B, Krasowska D. Is there any correlation between the total number of neutrophils in plasma and concentration of interleukin-8 in psoriatic patients? Med Sci Monit. 2000; 6:867–870.

24. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW. Interleukin-1: a key inflammatory mediator in psoriasis? Cytokine. 2006; 33:72–78.

25. Mizutani H, Ohmoto Y, Mizutani T, Murata M, Shimizu M. Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci. 1997; 14:145–153.

26. Johnston GI, Cook RG, McEver RP. Cloning of GMP-140, a granule membrane protein of platelets and endothelium: sequence similarity to proteins involved in cell adhesion and inflammation. Cell. 1989; 56:1033–1044.

27. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004; 104:1606–1615.

28. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C. Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release: a novel pathway for immune response amplification. J Immunol. 2004; 172:2011–2015.

29. Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of beta-thromboglobulin and platelet factor 4. Allergol Int. 2008; 57:391–396.